达安基因：2025年全年预计净亏损60700万元—86500万元

Core Viewpoint - The company DaAn Gene has released its annual performance forecast, expecting a significant net loss for 2025, primarily due to decreased revenue from market demand and policy impacts, despite some improvements in investment income from joint ventures [1] Group 1: Financial Performance - The expected net profit attributable to shareholders for 2025 is projected to be between -607 million to -865 million yuan [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between -938 million to -658 million yuan [1] Group 2: Revenue and Cost Factors - The decrease in revenue is attributed to market demand, the implementation of centralized procurement, and an increase in the value-added tax rate on self-produced reagent products to 13% [1] - Despite efforts to enhance operational efficiency and reduce costs, the fixed costs such as operational and labor costs remain high, leading to a negative impact on overall gross profit [1] Group 3: Investment and Asset Management - The performance of joint ventures has improved compared to the previous year, resulting in an increase in investment income recognized by the company [1] - The company has strengthened its collection of historical accounts receivable, leading to a reduction in the provision for credit impairment losses compared to the previous year [1] - A comprehensive asset review was conducted, and impairment tests were performed on assets showing signs of impairment, resulting in an increase in the provision for asset impairment losses compared to the previous year [1] Group 4: Non-Recurring Gains - The fair value of other non-current financial assets has increased, contributing to a rise in net profit attributable to shareholders compared to the previous year, with non-recurring gains before tax increasing by approximately 180 million yuan [1]